Macro Monthly 3 macro curves confirm economic strength

Evan Brown, Head of Multi-Asset strategy discusses the three market curves that could indicate an economic recovery.

01 Mar 2021

As multi-asset investors, we scrutinize the investable universe for signals that confirm or challenge our base case. 

In examining three important market-based curves and another relating to public health outcomes, we believe that we have found ample evidence to support our risk-on, procyclical bias and optimism on the global economic recovery. 

We will monitor the evolution of these curves to determine if and when the macroeconomic sands are shifting, and are prepared to adjust our positioning accordingly.

 

1. Steepening yield curve

The steepening of yield curves speaks to the combined monetary-fiscal support that is underwriting the nascent expansion until it reaches a much more mature phase

Economic optimism unlocked by the development of effective vaccines and enhanced by the promising outlook for continued US fiscal stimulus is being more fully reflected in global bond markets.

In early 2021, the bond sell-off was most concentrated in US Treasuries, but has more recently become more widely shared across advanced economies. The global backup in yields suggests a common catalyst, which we believe to be an increased conviction in a vigorous synchronized upswing across developed economies in the coming quarters, facilitated by successful vaccination campaigns. That credit markets are holding up fairly well amid this brisk rise in yields suggests that the bond sell-off is primarily a good-news message about the outlook for activity and inflation.

Fed officials, including Chair Jerome Powell, have yet to push back against the rise in longer-term yields. On the contrary, Powell seemingly welcomed this development as a sign that investors have confidence the US will have a robust, complete recovery. European Central Bank president Christine Lagarde, for her part, has displayed more concern on the potential for this backup in yields to adversely affect the nascent recovery on the continent.

Some of the bond market sell-off in the US relates to pulling forward expectations on Federal Reserve interest rate hikes. An aggressive extension of this trend, and accompanying rise in real yields and US dollar, could serve as a trigger for more disruption in equity markets as well as credit. We have seen some signs of this in the recent performance of high-duration growth stocks. Ultimately, we believe the Fed will overpower any overzealousness on the pricing of liftoff that tightens financial conditions or contradicts its forward guidance, as discussed in the February edition of Macro Monthly, The market will test the Fed. The Fed will win.

We remain short global duration, expecting further upwards pressure on yields across developed-market sovereign debt. The gap between two- and 10-year Treasury yields should continue to widen, in our view, as the Federal Reserve commits to holding off on rate hikes for the time being while longer-term borrowing costs reflect the discounting of a future in which it will eventually do so after dual mandate goals are achieved. As such, the message sent from the bond market affirms that we are poised to embark upon a period of strong economic growth during which procyclical positions should disproportionately benefit.

That global yield curves are steepening points to an expectation that central banks will remain accommodative for an extended period of time to allow the pandemic-induced economic damage to be repaired.

Long term bonds sell off on enhanced conviction in an eventual return to normal

Source: UBS-AM, Bloomberg. Data as of 24 February 2021

Long term bonds sell off on enhanced conviction in an eventual return to normal, charts net changes (basis points) in price spread between 2 year and 10 year government bonds for the US, Germany and United Kingdom.


 

2. Backwardated commodities curve

The commodities rally, and shape of those futures curves, point to the substantial rebound in demand and expectations for more to come.

Many commodity futures curves, such as crude oil and copper, are in a downward-sloping term structure known as backwardation.

Near-term contracts being priced higher than longer-dated futures is indicative of a market in which demand is outstripping supply. Accordingly, both crude and copper have posted robust gains in 2021. The advance in oil is attributable to both continued supply discipline from OPEC+ and an anticipated resurgence in demand. The crude curve thus reinforces the message from the vaccination curve – mobility will improve, and so too will demand for gasoline and, with a lag, jet fuel. The copper curve suggests that markets share our belief that any pullback in Chinese stimulus will not be abrupt, and that goods sectors will continue to perform well amid a rotation to services-led growth as vaccinations allow for progress towards pre-pandemic norms.

Tightening physical commodity markets are generally positive signals for cyclicals over defensives, emerging market currencies against the dollar, and negative for sovereign bonds. Backwardation also means that long commodity positions can generate positive roll yield over time, which can help increase the attractiveness of commodities as an asset class.

Term structure of commodity futures suggests physical market tightening

Source: UBS-AM, Bloomberg. Data as of 23 February 2021.

Term structure of commodity futures suggests physical market tightening, tracks the futures curve for crude oil and copper over several contract time periods.


 

3. Overly cautious VIX futures

The term structure of VIX futures suggest additional risk premium lingers in equity markets which could dissipate over time and buoy equities in the process.

Mix together high hedge fund equity exposure, retail exuberance, expensive valuations, and a near universally positive outlook for economic activity, and investors can reasonably wonder whether the biggest thing to fear about the equity market is the lack of fear itself. However, futures tied to the VIX Index – a gauge of the implied volatility for the S&P 500 Index based on out-of-the-money options prices that’s often called Wall Street’s “fear gauge” – paint a more nuanced picture on this front.

The VIX curve is generally in an upward-sloping structure called contango (the opposite of backwardation) for two reasons: Uncertainty about the outlook increases as a function of time, and US stocks are not typically in the kind of sharp drawdown that would have short-term measures of implied volatility trading above their longer-term counterparts.

At this time, the front of the VIX futures curve is an especially steep contango, ranging from 1 to 2.5 standard deviations above the 10-year mean throughout the first three weeks of February1. This suggests the curve is pricing a pronounced pick-up in market volatility in the not-too-distant future. In addition, longer-dated contracts trade at a significant premium to their historical averages. This is in part due to a continued imbalance in volatility markets, where supply continues to be constrained following the intense 2020 bear market.

This term structure sends a strong signal that complacency does not reign in US equities. We do not believe this persistent medium-term skittishness is warranted given the fundamentals. Elevated levels of market volatility are unlikely

to prevail for an extended period if our anticipated backdrop of a broad acceleration in economic activity and colossal earnings growth comes to pass. A compression in this fear premium could provide an additional tailwind for stocks in the months ahead.

VIX futures curve suggests elevated concern on the outlook for equities 

Source: UBS-AM, Bloomberg. Data as of 23 February 2021.

VIX futures curve suggests elevated concern on the outlook for equities, charts the price for futures tied to the VIX Index over a variety of options dates throughout 2021.

Conclusion – the key macro curves are all pointing in the right direction

Vaccinations are the necessary prerequisite for a sustainable economic recovery. The commodities rally, and shape of those futures curves, point to the substantial rebound in demand and expectations for more to come. The steepening of yield curves speaks to the combined monetary-fiscal support that is underwriting the nascent expansion until it reaches a much more mature phase. And the term structure of VIX futures suggest additional risk premium lingers in equity markets which could dissipate over time and buoy equities in the process.

These key macro curves are all pointing in the right direction. While these fortify our stance that there is more upside in global equities, we are even more enthusiastic about the relative value positions beneath the surface in stocks. For procyclical trades that are performing well lately – value stocks vs. growth, US equal weight relative to market cap indexes, and international equities vs. the US – there is considerably more room to run.
But we are cognizant that this bright, early-cycle backdrop will not persist in perpetuity. We will closely monitor shifts in these curves, along with other economic and market indicators, to judge whether the macroeconomic environment is changing or the procyclical rebound is fully priced into different asset classes.

At present, the widespread cross-asset corroboration for our constructive stance on global equities and negative view on sovereign bonds bolsters our confidence in sticking with what is working.

Subscribe now

Perspectives matter. Tune in to our insights.

 

Asset class attractiveness

The chart below shows the views of our Asset Allocation team on overall asset class attractiveness, as well as the relative attractiveness within equities, fixed income and currencies, as of 25 February 2021.

Source: UBS Asset Management Investment Solutions Macro Asset Allocation Strategy team as at 25 February 2021. Views, provided on the basis of a 3-12 month investment horizon, are not necessarily reflective of actual portfolio positioning and are subject to change.

  

The Asset class attractiveness (ACA) chart shows the views of our Asset Allocation team on overall asset class attractiveness, as well as the relative attractiveness within equities, fixed income and currencies, as of 25 February 2021.

More insights

Singapore Retail Investors

PLEASE READ THESE TERMS AND CONDITIONS CAREFULLY BEFORE PROCEEDING. BY UTILIZING THE WEBSITE AND PAGES THEREOF LOCATED AT WWW.UBS.COM/AM-SG ("WEBSITE"), YOU ACKNOWLEDGE THAT YOU HAVE READ THESE TERMS AS WELL AS THE GLOBAL TERMS OF USE (collectively "TERMS") AND THAT YOU AGREE TO BE BOUND BY THEM. IF YOU DO NOT AGREE TO ALL OF THE TERMS OF THIS AGREEMENT, YOU ARE NOT AN AUTHORIZED USER OF THESE SERVICES AND YOU SHOULD NOT USE THIS WEBSITE.

This website is not intended for and should not be accessed by persons located or resident in any jurisdiction where (by reason of that person's nationality, domicile, residence or otherwise) the publication or availability of this website is prohibited or contrary to local law or regulation or would subject any UBS entity to any registration or licensing requirements in such jurisdictions. It is your responsibility to be aware of, to obtain all relevant regulatory approvals, licenses, verifications and/or registrations under, and to observe all applicable laws and regulations of any relevant jurisdiction in connection with your entrance to this website. Each investment product and service referred to on this website is intended to be made available only to residents in Singapore.

UBS reserves the right to change, modify, add or remove content on the website as well as these terms at any time for any reason without notice. Such changes shall be effective immediately upon posting. You acknowledge that by accessing our website after we have posted changes to these terms, you are agreeing to these terms as modified.

The materials on this Website are distributed by UBS Asset Management (Singapore) Ltd (company registration number: 199308367C), which is licensed by Monetary Authority of Singapore ("MAS") in Singapore pursuant to the Securities and Futures Act (Chapter 289 of Singapore). UBS Asset Management (Singapore) Ltd is part of the Asset Management business division of UBS Group AG. UBS Asset Management (Singapore) Ltd together with UBS Group AG and its group companies shall collectively be referred to as "UBS".

The information contained in this Website has been prepared and is intended for general circulation. The information does not constitute advice and does not take into account the specific investment objectives, financial situation, or particular needs of any particular person. The investment services or products referred to in this Website may not be suitable for all investors. UBS recommends that you independently evaluate particular investments and strategies and seek independent advice from a financial adviser regarding the suitability of such investment products, taking into account your specific investment objectives, financial situation and particular needs, before making a commitment to purchase any investment products. Investment involves risks. You should be aware that investments may increase or decrease in value and that past performance is not indicative of future performance.

The information contained in this Website is not an offer to buy or sell or the solicitation of an offer to buy or sell any investment product or to participate in any particular trading strategy. UBS, its officers and/or employees may have interests in any of the investment products referred to on this Website by acting in various roles. UBS, its officers and/or employees may receive fees, commissions or other benefits for acting in those capacities. In addition, UBS, its officers and/or employees may buy or sell investment products as principal or agent and may effect transactions which are not consistent with the information set out in this Website.

You fully understand and agree that, by making available this Website, UBS should not be construed as making: (a) any endorsement of any investment product referred to in this Website; (b) any representation that UBS has performed any due diligence on any investment product referred to in this Website; or (c) any representation that the information in this Website is complete, accurate, clear, fair and not misleading. The use or reliance on any such information contained in this Website is at your own risk and any losses which may be suffered as a result of you entering into any investment are for your account and UBS shall not be liable for any losses arising from or incurred by you in connection therewith. UBS is not responsible or liable for the accuracy and completeness of any such information or the performance or outcome of any investment made by you after receipt of such information, irrespective of whether such information was provided at your request.

Using, copying, redistributing or republishing any part of this Website without prior written permission from UBS is prohibited. Any statements made regarding investment performance objectives, risk and/or return targets shall not constitute a representation or warranty that such objectives or expectations will be achieved or risks are fully disclosed. The information and opinions contained in this Website is based upon information obtained from sources believed to be reliable and in good faith but no responsibility is accepted for any misrepresentation, errors or omissions. All such information and opinions are subject to change without notice. A number of comments in this Website are based on current expectations and are considered “forward-looking statements”. Actual future results may prove to be different from expectations and any unforeseen risk or event may arise in the future. The opinions expressed are a reflection of UBS’s judgment at the time this document is compiled and any obligation to update or alter forward-looking statements as a result of new information, future events, or otherwise is disclaimed.

UBS does not hold out any of its officers and/or employees as having any authority to advise you, and UBS does not purport to advise you on any investment product. Any investment will be made at your sole risk and UBS is not and shall not, in any manner, be liable or responsible for the consequences of any investment.

This Website and its contents are provided on an “as is” and “as available” basis. UBS does not warrant: (a) the accuracy, timeliness, adequacy commercial value or completeness of this Website or its contents, and expressly disclaims any liability for errors, delays or omissions in the contents, or for any action taken in reliance on the contents; (b) that your use of and/or access to this Website or its contents, will be uninterrupted, timely, secure or free from errors or that any identified defect will be corrected; (c) that this Website or any content will meet your requirements or are free from any virus or other malicious, destructive or corrupting code, agent, program or macros; (d) that any information, instructions or communications posted or transmitted by you through this Website is secure and cannot be accessed by unauthorised third parties; and (e) that use of the contents in this Website by you will not infringe the rights of any third parties. No warranty of any kind, implied, express or statutory, including but not limited to the warranties of non-infringement of third party rights, title, merchantability, satisfactory quality or fitness for a particular purpose and freedom from computer virus or other malicious, destructive or corrupting code, agent, program or macros, is given in conjunction with this Website.

You hereby agree to indemnify UBS and any of its officers, employees or agents against, and to keep UBS and any of its officers, employees or agents harmless from, any claims (actual and threatened), settlement sums, liability, loss, damages, costs (including solicitor and client costs and expenses (legal or otherwise)), charges, expenses, actions, proceedings, whether foreseeable or not which we may sustain, suffer or incur, directly or indirectly out of or in the course of or in connection with any the following: (a) any use of this Website or the contents by you, or any part thereof; (b) UBS having made available the Website; (c) any breach of these Terms by you, however arising; or (d) any negligence, act or omission, wilful default, unlawful act, fraud and/or misconduct on your part or violation of any rights of another person or entity by you.

The funds referred to in this Website have been authorised or recognised by the MAS for sale to the public in Singapore (the “Funds”). Copies of the registered Singapore prospectuses ("Prospectuses") referred to in this Website have been lodged with and registered by the MAS. The MAS assumes no responsibility for the contents of the Prospectuses. The registration of the Prospectuses by the MAS does not imply that the SFA or any other legal or regulatory requirements have been complied with.

MAS registration is not a recommendation or endorsement of a Fund nor does it guarantee the commercial merits or performance of such Fund. It does not mean that a Fund is suitable for all investors nor is it an endorsement of its suitability for any particular investor or class of investors. UBS Asset Management (Singapore) Ltd has been appointed as the representative for the Funds in Singapore for the purposes of performing administrative and other related functions relating to the offer of Shares under Section 287 of the Securities and Futures Act, Chapter 289 of Singapore (the "SFA") and such other functions as the MAS may prescribe.

You may not assign your rights under the Terms without our prior written consent. UBS Asset Management (Singapore) Ltd may assign our rights under the Terms to any third party.

No person or entity who is not a party to the Terms shall have any right under the Contracts (Rights of Third Parties) Act, Chapter 53B of Singapore or other similar laws to enforce any term of the Terms regardless of whether such person or entity has been identified by name, as a member of a class or as answering a particular description. For the avoidance of doubt, this shall not affect the rights of any permitted assignee or transferee of the Terms.

These Terms shall be governed by, and shall be construed in accordance with, the laws of Singapore. The courts of Singapore shall have exclusive jurisdiction to hear and determine any suit, action or proceeding, and to settle any disputes, which may arise out of or in connection with these Terms and, for such purposes, you agree to submit  to the jurisdiction of the courts of Singapore. Each party hereby waives any objection which it might at any time have to the courts of Singapore being nominated as the forum to hear and determine any proceedings and to settle any disputes and agrees not to claim that the courts of Singapore are not a convenient or appropriate forum.

© UBS 2021 - the key symbol and UBS are among the registered and unregistered trademarks of UBS. All rights reserved.

Reset